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The value of combining Dukes’ stage and C-reactive protein to form a cumulative prognostic score was assessed in 147 patients
undergoing potentially curative resection for colorectal cancer. The cancer-specific survival rates at 3 years for patients with a
cumulative prognostic score of 0, 1 and 2 were 100, 77 and 40%, respectively (HR 4.76, 2.78–8.15, Po0.001).
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Colorectal cancer is the second commonest cause of cancer death
in North America and Western Europe. Each year in the UK, there
are approximately 27000 new cases and approximately 18000
deaths attributable to the disease. Overall survival is poor; even in
those who undergo potentially curative resection, only half survive
5 years (McArdle et al, 2003).
The ideal prognostic score for patients undergoing potentially
curative resection of a primary colorectal cancer should clearly
distinguish those who will eventually succumb to the disease from
those who are cured. While Dukes’ stage has been widely used, it
fails to provide clear separation between these groups. Alternative
factors that would provide additional information to that of Dukes’
staging are therefore required.
There is increasing evidence that the presence of a systemic
inflammatory response, as evidenced by elevated circulating
concentrations of C-reactive protein, is associated with increased
recurrence and poor survival in patients undergoing potentially
curative surgery for colorectal cancer (McMillan et al, 1995, 2003;
Nozoe et al, 1998; Nielsen et al, 2000; Wigmore et al, 2001; Chung
and Chang, 2003). However, some of these studies have questioned
whether C-reactive protein has prognostic value independent of
conventional pathological criteria including Dukes’ stage (Wig-
more et al, 2001; Chung and Chang, 2003).
The aim of the present study was to assess whether or not an
elevated circulating C-reactive protein concentration has prog-
nostic value independent of conventional clinicopathological
criteria in patients undergoing potentially curative resection for
colorectal cancer.
PATIENTS AND METHODS
Patients
Patients with Dukes’ B and C colorectal cancer, who, on the basis
of laparotomy findings and pre-operative computed tomography,
underwent potentially curative resection between January 1997 and
September 2001 in a single surgical unit at the Glasgow Royal
Infirmary, were included in the study. Patients who had pre-
operative radiotherapy were excluded from the study.
Prior to surgery, a blood sample was taken for routine
laboratory measurement of albumin and C-reactive protein. At
this time, no patient showed clinical evidence of tumour
metastases, infection, or other inflammatory conditions. The
tumours were staged using conventional Dukes’ classification
(Dukes and Bussey, 1958). All patients were followed-up at a single
specialist colorectal cancer clinic.
The study was approved by the local ethical committee.
Statistics
Data are presented as median and range. Comparisons between
groups of patients were carried out using contingency table
analysis (w
2). Grouping of the variables age, albumin and C-
reactive protein was carried out using standard thresholds
(Scottish Cancer Intelligence Unit, 2000; O’Gorman et al, 2000;
Forrest et al, 2003).
Survival (cancer-specific) analysis was performed using the Cox
proportional hazard model. Deaths up to September 2003 have
been included in the analysis. Multivariate survival analysis
was performed using a stepwise backward procedure to derive a
final model of the variables that had a significant independent
relationship with survival. To remove a variable from the
model, the corresponding P-value had to be greater than 0.10.
Analysis was performed using SPSS software (SPSS Inc., Chicago,
IL, USA).
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The baseline clinicopathological characteristics of the patients
(n¼147) who underwent potentially curative surgery for color-
ectal cancer are shown in Table 1. Approximately one-third of
patients were aged 75 or over. The majority had colonic tumours,
were Dukes’ stage B and had moderately differentiated tumours. In
all, 53 (36%) patients had an elevated C-reactive protein
concentration prior to surgery. A total of 31 patients received 5-
FU-based chemotherapy.
The minimum follow-up was 24 months; the median follow-up
of the survivors was 56 months. During this period 45 patients
died, 31 patients of their cancer and 14 of intercurrent disease.
On univariate analysis, increased age (Po0.001), sex (Po0.05),
Dukes’ stage (Po0.001), elevated circulating C-reactive protein
concentrations (Po0.001) and venous invasion (Po0.05) were
associated with poor cancer-specific survival. On multivariate
analysis, including the above variables, age (HR 1.97, 95% CI 1.21–
3.23, P¼0.008), Dukes stage (HR 5.47, 95% CI 2.50–11.99,
Po0.001) and C-reactive protein (HR 4.27, 95% CI 1.94–9.41,
Po0.001) were significantly associated with cancer-specific
survival.
Since the magnitude of the covariates of Dukes’ stage (1.70) and
C-reactive protein (1.45) were similar, this indicates that a one unit
increase in C-reactive protein had approximately the same relative
risk as a one unit increase in pathological stage and that they could
be simply added to form a prognostic score. Such a cumulative
prognostic score was therefore constructed by assigning one point
for each of the following criteria: Dukes’ stage C and C-reactive
protein 410mgl
 1.
The relationship between stage, C-reactive protein concentra-
tion, the cumulative prognostic score and cancer-specific mortality
is shown in Table 2. The relationship between the cumulative
prognostic score and cancer-specific survival is shown in Figure 1.
The cancer-specific survival rates at 3 years for patients with a
cumulative prognostic score of 0, 1 and 2 were 100, 77 and 40%,
respectively (HR 4.76, 95% CI 2.78–8.15, Po0.001).
DISCUSSION
Several studies have shown that elevated circulating C-reactive
protein concentrations are associated with poor survival in
patients with colorectal cancer (McMillan et al, 1995; Nozoe et al,
1998; Nielsen et al, 2000; Wigmore et al, 2001; McMillan et al, 2003;
Chung and Chang, 2003). However, the relationship between C-
Table 1 Clinicopathological characteristics in patients with colorectal cancer: univariate survival analysis
Patients (n¼147) Hazard ratio (95% CI) P-value
Age group (o65/65–74/X75) 46/44/57 2.33 (1.42–3.83) o0.001
Sex (male/female) 78/69 2.11 (1.03–4.36) 0.043
Site (colon/rectum) 105/42 1.38 (0.60–3.21) 0.451
Dukes stage (B/C) 91/56 5.07 (2.33–11.02) o0.001
Albumin (o35/X35gl
 1) 31/116 0.86 (0.33–2.26) 0.766
C-reactive protein (o10/p10mgl
 1) 94/53 5.02 (2.35–10.74) o0.001
Tumour characteristics
Diameter (tertiles) 49/49/49 1.02 (0.67–1.56) 0.927
Ulceration (no/yes) 72/75 1.20 (0.59–2.43) 0.611
Differentiation (well/moderate/poor) 18/116/13 1.57 (0.70–3.50) 0.274
Lymphatic invasion (negative/positive) 124/22 1.83 (0.79–4.26) 0.158
Venous invasion (negative/positive) 118/28 2.43 (1.14–5.16) 0.021
Adjuvant therapy (no/yes) 116/31 1.13 (0.49–2.62) 0.779
Table 2 Prognostic score following curative resection for colorectal cancer
Dukes’ stage C-reactive protein
Stage Score (mgl
 1) Score Cumulative score Patients (n) 3-year survival rate (%)
B0 p10 0 0 61 100
410 1 1 30 80
C1 p10 0 1 33 77
410 1 2 23 40
Cumulative score obtained by adding scores for Dukes’ stage and C-reactive protein.
Survival (months)
36 30 24 18 12 6 0
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Figure 1 The relationship between the cumulative prognostic score (0
...., 1--, 2—) and cancer-specific survival following potentially curative
surgery for colorectal cancer.
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gical criteria is not clear, since some of the above studies have
included patients with Dukes A tumours who were unlikely to
progress and patients with Dukes D tumours who had already
progressed (Wigmore et al, 2001; Chung and Chang, 2003). This is
likely to have confounded the assessment of the prognostic value
of an elevated circulating C-reactive protein concentration.
In the present study, both Dukes’ stage and C-reactive protein
concentrations were independently associated with cancer-specific
survival. These results are consistent with those of Nielsen and co-
workers (2000) who, in a cohort of almost 400 patients undergoing
resection for Dukes B and C tumours, also demonstrated that C-
reactive protein was a Dukes’ stage independent prognostic factor.
The mechanism by which a systemic inflammatory response might
influence cancer survival is not clear. However, it is known that as
part of the systemic inflammatory response, there is a release of
pro-inflammatory cytokines and growth factors which may
promote tumour growth (Abramovitch et al, 1999) and compro-
mise immune function (Coussens and Werb, 2002).
In the present study, when C-reactive protein concentrations
were combined with Dukes’ stage to form a new prognostic score,
the combined score improved the prediction of cancer-specific
survival. The addition of C-reactive protein differentiated between
low- and high-risk Dukes’ B and low- and high-risk Dukes’ C
patients. Cancer-specific survival at 3 years ranged from 100% in
patients with Dukes’ B tumours and a normal C-reactive protein
concentration to 40% in patients with Dukes’ C tumours and an
elevated C-reactive protein concentration. Cancer-specific survival
in patients with Dukes’ B tumours and an elevated C-reactive
protein concentration was similar to that of patients with Dukes’ C
tumours and a normal C-reactive protein concentration. There-
fore, this cumulative prognostic score may be useful in identifying
high-risk Dukes’ B patients suitable for adjuvant therapy.
The results of the present study indicate that this simple
prognostic score, which reflects both the contribution of the
tumour and the host response, differentiates between low- and
high-risk Dukes’ B and C tumours in patients undergoing
potentially curative resection for colorectal cancer.
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